ADVERTISEMENT

Clinical Summary

Durvalumab±tremelimumab+chemotherapy for non-small cell lung cancer

Miriam Davis, PhD   |   17 November 2022

Takeaway

  • The 3-arm POSEIDON phase 3 trial found that tremelimumab (an anti-CTLA-4 monoclonal antibody) in combination with durvalumab and chemotherapy (T+D+CT) as first-line therapy for metastatic NSCLC significantly improved PFS and OS.
  • D+CT significantly improved PFS but not OS.

Why this matters

  • T is thought to work by a complementary mechanism...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right